Please assess the completion status of the following clinical trial:

Trial Title: ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Primary Inclusion Criteria:~* Health care professional (eg, physician, osteopath, nurse, pharmacist)~* 18 years of age or older~* Enrolled or enrolling in an extended outpatient treatment program for opioid dependence~* Women of childbearing potential must agree to use an approved method of contraception for the duration of the study~Primary Exclusion Criteria:~* Pregnancy and/or lactation~* Evidence of hepatic failure~* Active hepatitis~* Any psychiatric disorder that would compromise ability to complete study requirements~* Recent history of suicidal ideation or attempt~* Current dependence to any drugs other than prescription opioids or heroin, benzodiazepines, caffeine, marijuana, alcohol, or nicotine~* Positive urine drug test or self-reported use of opioids, cocaine, or amphetamines at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Medisorb naltrexone 380 mg (VIVITROL) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).